NAPP Logo
  • NAPP logo
  • About Us
  • Products
  • Working at Napp
  • Partnering
    • Commercial partnering
    • Joint working
  • Education
    • NAPP Academy
  • Media
    • News
    • Press Releases
  • Contact
  • Home
  • About Us
  • Products
  • Working at Napp
  • Partnering
  • Education
  • Media
  • Contact

All Press Releases

Image for Napp Pharmaceuticals Announces European Commission Approval of Invokana® (canagliflozin) Label Update to Reflect Improved Renal Outcomes in Patients With Diabetic Kidney Disease and Type 2 Diabetes
Napp Pharmaceuticals Announces European Commission Approval of Invokana® (canagliflozin) Label Update to Reflect Improved Renal Outcomes in Patients With Diabetic Kidney Disease and Type 2 Diabetes

July 2, 2020

Image for CHMP issues positive opinion to extend Invokana® (canagliflozin) indication to reflect improved renal outcomes in patients with diabetic kidney disease and type 2 diabetes
CHMP issues positive opinion to extend Invokana® (canagliflozin) indication to reflect improved renal outcomes in patients with diabetic kidney disease and type 2 diabetes

May 29, 2020

Image for Type 2 Diabetics miss out on a recommended annual kidney test which can signal irreversible damage that may lead to fatal complications, survey reveals
Type 2 Diabetics miss out on a recommended annual kidney test which can signal irreversible damage that may lead to fatal complications, survey reveals

February 20, 2020

Image for Statement on the Public Health England Review on prescribed medicines that may cause dependence or withdrawal
Statement on the Public Health England Review on prescribed medicines that may cause dependence or withdrawal

September 10, 2019

Image for CREDENCE Subgroup Analysis Finds Significant Reduction of Major Cardiovascular Events and Kidney Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease
CREDENCE Subgroup Analysis Finds Significant Reduction of Major Cardiovascular Events and Kidney Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease

June 12, 2019

Image for Improving support for people who are prescribed medicines that have the potential to cause addiction, dependence or withdrawal symptoms
Improving support for people who are prescribed medicines that have the potential to cause addiction, dependence or withdrawal symptoms

April 30, 2019

Image for Landmark Phase 3 ‘CREDENCE’ study shows significant reduction of risk of renal failure in patients with type 2 diabetes and chronic kidney disease
Landmark Phase 3 ‘CREDENCE’ study shows significant reduction of risk of renal failure in patients with type 2 diabetes and chronic kidney disease

April 15, 2019

Image for Napp launches Pelmeg®▼(biosimilar pegfilgrastim) in the UK
Napp launches Pelmeg®▼(biosimilar pegfilgrastim) in the UK

March 1, 2019

Image for flutiform® pMDI to be available for treatment of children 5+ with asthma
flutiform® pMDI to be available for treatment of children 5+ with asthma

January 11, 2019

Image for European Commission expands labelling for INVOKANA▼® and VOKANAMET▼® to include positive data on cardiovascular and renal outcomes
European Commission expands labelling for INVOKANA▼® and VOKANAMET▼® to include positive data on cardiovascular and renal outcomes

September 7, 2018

Image for CHMP issues positive opinion to expand Invokana▼® (canagliflozin) and Vokanamet▼® (canagliflozin and metformin), labels to include positive data on cardiovascular and renal outcomes
CHMP issues positive opinion to expand Invokana▼® (canagliflozin) and Vokanamet▼® (canagliflozin and metformin), labels to include positive data on cardiovascular and renal outcomes

August 2, 2018

Image for Napp welcomes positive phase III efficacy findings for Invokana▼® (canagliflozin) in type 2 diabetes patients with chronic kidney disease
Napp welcomes positive phase III efficacy findings for Invokana▼® (canagliflozin) in type 2 diabetes patients with chronic kidney disease

July 23, 2018

Image for Asthma device, k-haler®, celebrates two A’ Design Award & Competition wins
Asthma device, k-haler®, celebrates two A’ Design Award & Competition wins

April 25, 2018

Image for Napp sponsors Clinical Pharmacy Congress
Napp sponsors Clinical Pharmacy Congress

April 24, 2018

Image for Statement from Napp on the treatment of chronic pain with opioid analgesics
Statement from Napp on the treatment of chronic pain with opioid analgesics

April 6, 2018

Image for Napp expands biosimilar portfolio with exclusive UK partnership deal for trastuzumab biosimilar, Herzuma▼®
Napp expands biosimilar portfolio with exclusive UK partnership deal for trastuzumab biosimilar, Herzuma▼®

March 27, 2018

Image for Napp secures appointment as exclusive distributor of Invokana▼® in the UK
Napp secures appointment as exclusive distributor of Invokana▼® in the UK

September 6, 2017

Image for New algorithm provides GPs and asthma nurses with vital guidance on ‘stepping down’
New algorithm provides GPs and asthma nurses with vital guidance on ‘stepping down’

July 11, 2017

Image for Napp welcomes new General Manager
Napp welcomes new General Manager

March 1, 2017

Stay connected

  • Legal
  • Cookie Policy
  • Privacy Notice
  • Registered Company
  • Modern Slavery Statement
  • Integrity Line
  • Tax Strategy
  • Group Pension Scheme
  • PENSION IMPLEMENTATION STATEMENT
  • Statement of Investment Principles
© 2022 NAPP Pharmaceuticals Limited. Last updated: May 2019

You are now leaving our website. Napp does not accept any responsibility for the third party site.

Please click "Continue to external link" if you want to proceed.

Go Back
Continue to external link

This website uses cookies so that we can provide you with the best user experience possible.

 

Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

 

We use necessary cookies to ensure the proper functioning of our site.

 

We'd also like to set optional analytics cookies to help us to improve your experience when using the site. We won't set optional cookies unless you choose to enable them. Using this tool will place a cookie on your device which will remember your preferences when you next visit.

 

For more detailed information about the cookies we use, please refer to our Cookie Policy. Settings.

Napp
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!

Cookie Policy

More information about our Cookie Policy